Polymorphisms in fatty acid binding protein 5 show association with type 2 diabetes.

Diabetes Res Clin Pract

Center for Health Disparities and Molecular Medicine and Department of Basic Sciences, Loma Linda University, School of Medicine, Loma Linda, CA 92350, United States.

Published: April 2011

Genes for the fatty acid binding proteins (FABP) family encode small 14-15 kDa cytosolic proteins and can be regulated during type 2 diabetes mellitus (T2DM) and obesity. This study compared association of single nucleotide polymorphisms (SNPs) in FABP1-5 with T2DM in different ethnic groups. Associations with T2DM of SNPs in these proteins were assessed in African American (AA), non-Hispanic White (NHW), and Hispanic American (HA) individuals. A total of 650 DNA samples were genotyped; control samples were obtained from Coriell's North American Human Variation Panel Repository (NAHVP) of apparently healthy individuals and T2DM cases were taken from the American Diabetes Association GENNID Study. The rs454550 SNP of FABP5 showed a significant association with T2DM in NHW (OR: 9.03, 95% CI: 1.13-71.73, p=0.014). Our analysis also identified a new FABP5 SNP (nSNP) that showed a significant association with T2DM in NHW (OR: 0.44, 95% CI: 0.19-0.99, p=0.045) and AA (OR: 0.17, 95% CI: 0.03-0.80, p=0.016). The Ala54Thr FABP2 polymorphism was significantly associated with T2DM in HA individuals only (OR: 1.85, 95% CI: 1.05-3.27, p=0.032). All other FABP SNPs did not show association with T2DM. These findings suggest a potential distinct role(s) of SNPs in FABP5 and FABP2 genes in T2DM in different populations.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3078975PMC
http://dx.doi.org/10.1016/j.diabres.2011.01.005DOI Listing

Publication Analysis

Top Keywords

association t2dm
12
t2dm
9
fatty acid
8
acid binding
8
type diabetes
8
t2dm nhw
8
association
6
polymorphisms fatty
4
binding protein
4
protein association
4

Similar Publications

Aims: This study evaluated the effects of circuit resistance training (CRT), a vegetarian/Mediterranean diet (VegMedD), and empagliflozin on Resting Metabolic Rate (RMR) in older adults with Type 2 Diabetes (T2DM).

Methods: 67 participants from CEV-65 trial (≥65 years, 61 % female) were randomly assigned to CRT, VegMedD, or empagliflozin for 10 weeks. Assessments included RMR, medical, metabolic, nutritional, anthropometric and functional measurements.

View Article and Find Full Text PDF

Introduction: Globally, chronic kidney disease (CKD) has emerged as one of the leading causes of mortality and it is one of a small number of noncommunicable diseases that have shown an increase in associated deaths over the past two decades. Chronic kidney disease affects approximately 50% of patients with type 2 diabetic mellitus (DM).

Objective: To determine CKD preventive attitude, practices, and associated factors among type 2 DM (T2DM) patients attending follow-up in a diabetic clinic at Asella Referral and Teaching Hospital.

View Article and Find Full Text PDF

Early detection of cognitive dysfunction in patients with type 2 diabetes mellitus (T2DM) is important for preventive measures due to the lack of effective treatments. The purpose of this study is to investigate the relationship between enlarged perivascular space in the hippocampus (H-EPVS) and cognitive performance in patients with T2DM, and to determine whether it can serve as an imaging marker for cognitive dysfunction. 66 T2DM patients with cognitive impairment (T2DM-CI) and 71 T2DM patients with normal cognitive function (T2DM-NC) underwent cranial MRI scans and comprehensive neuropsychological assessments.

View Article and Find Full Text PDF

Background: Lifestyle interventions have been acknowledged as effective strategies for preventing type 2 diabetes mellitus (T2DM). However, the accessibility of conventional face-to-face interventions is often limited. Digital health intervention has been suggested as a potential solution to overcome the limitation.

View Article and Find Full Text PDF

Acetonemic vomiting: a potential complication of treatment with glucagon-like peptide-1 receptor agonists especially in lean type 2 diabetes patients.

Diabetol Int

January 2025

Division of Diabetes and Metabolic Diseases, Department of Internal Medicine, Nihon University School of Medicine, 30-1 Oyaguchi Kami-cho, Itabashi-ku, Tokyo 173-8610 Japan.

Objectives: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are now widely used for treating type 2 diabetes mellitus (T2DM) and obesity. We examined their association with acetonemic vomiting, especially when given to patients with low body weight, in hopes of achieving early recognition of this complication which is potentially life-threatening if not dealt with appropriately.

Methods: Cases identified incidentally are described and discussed referring to prior reports.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!